Netarsudil

Netarsudil
Clinical data
Pronunciation	ne TAR soo dil
Trade names	Rhopressa, Rhokiinsa
Other names	AR-11324
AHFS/Drugs.com	Monograph
MedlinePlus	a618014
License data	US DailyMed: Netarsudil;
Routes of; administration	Eye drops, topical
ATC code	S01EX05 (WHO) ;
Legal status
Legal status	US: ℞-only ; EU: Rx-only [1];
Identifiers
	IUPAC name [4-[(2S)-3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;
CAS Number	1254032-66-0;
PubChem CID	66599893;
DrugBank	DB13931;
ChemSpider	34980598;
UNII	W6I5QDT7QI;
KEGG	D11030; as salt: D11031;
ECHA InfoCard	100.251.524
Chemical and physical data
Formula	C28H27N3O3
Molar mass	453.542 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3;
	InChI InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1; Key:OURRXQUGYQRVML-AREMUKBSSA-N;

Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. In the United States in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2][3] It targets the trabecular meshwork directly.[4]

The FDA considers it to be a first-in-class medication.[5]

References

"Netarsudil". Drug Information Portal. U.S. National Library of Medicine.
"Netarsudil mesylate". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.